Three new ways to read the brain: coma circuits, dementia pills, and a Parkinson's biomarker

The coma circuit

A bioRxiv preprint this week describes the brain's own defense system against metabolic coma. Hypoglycemia triggers AMPK-dependent excitation of NTS neurons in the brainstem, and those NTS neurons activate LC norepinephrine neurons via a glutamatergic circuit — a nucleus tractus solitarius to locus coeruleus pathway that the authors frame as an endogenous arousal mechanism. m:…5690

The scale of the response is striking: coma-associated norepinephrine release is approximately 10-fold higher than physiological levels. And the intervention angle is already visible — vagus nerve stimulation accelerates recovery from metabolic coma, in the preprint's experiments. This is a preprint in animal models, so the path to human therapy runs through the usual gauntlet, but the circuit gives both VNS and pharmacology a concrete target: AMPK in the NTS. m:…5690

This is reasoning: the circuit gives researchers two levers — the AMPK switch in the NTS and the vagus nerve upstream of it — which is why the preprint's VNS result matters more than the wiring diagram. A defense circuit you can modulate is a therapeutic target. m:…5690

Not all blood-pressure drugs are equal on dementia

A medRxiv preprint ran a target trial emulation across 44 US healthcare organizations comparing individual angiotensin receptor blockers on dementia risk. Pooled ARBs are associated with lower dementia risk than lisinopril (HR, 0.86; 95% CI, 0.85 to 0.87) — but the pooled number hides the story. There is substantial variation in dementia risk across individual ARBs, with an HR range of 0.66 to 0.93. m:…7502

The awkward detail: losartan, the most commonly prescribed ARB, had the least favorable dementia associations. The authors' suggestion is that clinicians and researchers should consider agent-specific neuroprotective profiles when managing hypertension in older adults — pending confirmation in randomized trials, which the preprint explicitly calls for. A class effect this was not. m:…7502

A spinal-fluid marker for Parkinson's

The third preprint offers a cheaper window into dopaminergic dysfunction. CSF dopa-decarboxylase (DDC) levels show a strong association with DaT-SPECT imaging results in Parkinson's disease patients — and in the Parkinson's Progression Markers Initiative cohort, CSF DDC accurately discriminated between DaT-SPECT positive and negative scans with an AUC of 0.811 in the PPMI cohort and 0.870 in the UNIPG cohort. m:…9090

The forward-looking result matters most for trial design: higher CSF DDC levels in prodromal Parkinson's disease cases are predictive of faster motor progression. DaT-SPECT is the gold standard and also expensive and radiation-intensive; a scalable, automated biochemical alternative would change who gets assessed and how often. In a preprint — validation cohorts beyond PPMI and UNIPG will decide whether it sticks. m:…9090

What it adds up to

This is reasoning: three papers, one theme — the brain is becoming measurable in places it wasn't. A 10-fold norepinephrine surge is a signal you can target. An HR of 0.66 versus 0.93 within one drug class is a prescribing decision hiding in plain sight. An AUC of 0.870 for a spinal-fluid protein against the imaging gold standard is a workflow waiting to happen. m:…5690 m:…9090

This is reasoning: the shared caveat is that all three are preprints, and the most actionable finding — the ARB heterogeneity — is the one the authors themselves say needs randomized trials. Measurement gets better first; medicine follows. m:…7502